| DIRECT COMPETITOR COMPARISON | |
| PARD | BMY | IMGN | SNY | Industry | | Market Cap: | 58.04M | 48.04B | 368.25M | 94.76B | 107.08M | | Employees: | 59 | N/A | 210 | 98,213 | 59 | | Qtrly Rev Growth (yoy): | N/A | -4.10% | -66.70% | 8.50% | 19.70% | | Revenue (ttm): | N/A | 18.81B | 18.74M | N/A | 13.84M | | Gross Margin (ttm): | N/A | 73.28% | -143.15% | 75.20% | 66.58% | | EBITDA (ttm): | -41.29M | 5.84B | -34.42M | N/A | -12.25M | | Oper Margins (ttm): | N/A | 27.46% | -210.30% | N/A | -158.08% | | Net Income (ttm): | -46.99M | 3.17B | -40.82M | N/A | N/A | | EPS (ttm): | -1.354 | 5.376 | -0.753 | N/A | -0.31 | | P/E (ttm): | N/A | 4.51 | N/A | N/A | 17.08 | | PEG (5 yr expected): | N/A | 4.65 | N/A | 2.44 | 1.15 | | P/S (ttm): | N/A | 2.55 | 19.66 | N/A | 9.82 |
|
| BMY = Bristol-Myers Squibb Company | | IMGN = Immunogen Inc. | | SNY = Sanofi-Aventis | | Industry = Biotechnology | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.21 | 0.00% | 56.92B | 12.69 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 54.09 | 0.00% | 15.64B | 18.10 | | Genzyme Corp. | GENZ | 54.87 | 0.00% | 14.56B | 31.28 | | Merck Serono S.A. | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.30 | 0.00% | 41.66B | 16.41 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 47.82 | 0.00% | 8.54B | 59.92 | | Teva Pharmaceutical Industries Limited | TEVA | 57.10 | 0.00% | 50.31B | 52.24 | | Sandoz International GmbH | Private - View Profile |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Watson Pharmaceuticals Inc. | WPI | 38.10 | 0.00% | 4.04B | 19.64 | | King Pharmaceuticals Inc. | KG | 11.44 | 0.00% | 2.84B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.68 | 0.00% | 5.40B | 108.47 | | Pfizer Inc. | PFE | 17.88 | 0.00% | 144.28B | 14.85 | | Johnson & Johnson | JNJ | 62.76 | 0.00% | 173.16B | 14.27 | | GlaxoSmithKline plc | GSK | 38.47 | 0.00% | 97.52B | 12.91 | | Sanofi-Aventis | SNY | 36.29 | 0.00% | 94.76B | N/A | | Novartis AG | NVS | 53.58 | 0.00% | 121.69B | 16.04 | | RHHBY.PK | 41.50 | 0.00% | N/A | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | AstraZeneca plc | AZN | 44.11 | 0.00% | 64.00B | 8.50 | | Abbott Laboratories | ABT | 53.35 | 0.00% | 82.52B | 14.44 | | Bristol-Myers Squibb Company | BMY | 24.25 | 0.00% | 48.04B | 4.51 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | SNY | | Sanofi-Aventis quarterly net income up 10%
Wed 2:36am -
at MarketWatch | | • | SNY | | Sanofi-aventis Video Q&A : CEO Chris Viehbacher Comments on 2009 Full-Year Earnings
Wed 1:35am -
Business Wire | | • | BMY | | Pfizer Off 2% As 2010 Targets Miss; Posts Revised 2012 Targets
Tue 8:20pm -
at Barrons.com | | • | BMY | | Researchers find sex-specific lung cancer genes
Tue 7:34pm -
at Reuters | | • | BMY | | How Much Should Cancer Drugs Cost?
Tue 4:05pm -
at The Wall Street Journal Online | | • | BMY | | Make Thousands From Millions
Tue 1:20pm -
at Motley Fool | | • | SNY | | Bone Up On This Potential Blockbuster
Tue 11:58am -
at Motley Fool | | • | SNY | | Europe Launches Probe into Pharma Deals
Tue 10:52am -
at BusinessWeek | | • | SNY | | Germany Cancels Swine Flu Vaccines
Tue 10:52am -
at BusinessWeek | | • | BMY | | UPDATE - U.S. FDA staff questions small ChemGenex study
Mon, Feb 8 -
at Reuters | | • | BMY | | UK says Novartis, Bristol cancer drugs too costly
Mon, Feb 8 -
at Reuters | | • | BMY | | Monday Options Recap: Volatility Eases
Mon, Feb 8 -
at Seeking Alpha | | • | BMY | | Correction is Healthy - and a Buying Opportunity: Strategist
Mon, Feb 8 -
at CNBC | | • | IMGN | | IMMUNOGEN INC Financials
Wed, Feb 3 -
EDGAR Online Financials | | • | IMGN | | ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on February 25, 2010
Wed, Feb 3 -
Business Wire | | • | IMGN | | ImmunoGen, Inc. Announces Webcast of Presentation at the 12th Annual BIO CEO & Investor Conference
Tue, Feb 2 -
Business Wire | | • | IMGN | | Biotech Calendar: Key Dates for February
Tue, Feb 2 -
at TheStreet.com | | • | IMGN | | New Star Analyst Rankings for ImmunoGen, Inc.
Sat, Jan 30 -
StarMine | | | All Headlines for these symbols... |
|
|
|
1.52% Nasdaq 0.00%
Competitors
